Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration247
Changes in the amyloid editorial board members and in editor positions244
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies102
A second case of liraglutide-type localised amyloidosis89
Impact of autonomic dysfunction in light chain amyloidosis patient with nephrotic syndrome and cardiac involvement68
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey54
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study43
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases30
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis28
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging23
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains22
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Genetic landscape of hereditary transthyretin amyloidosis in Spain: a multicentric retrospective study17
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis16
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay16
Alterations in multi-layer strain in AL amyloidosis15
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival15
Management of AL amyloidosis in 2021+14
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque14
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice13
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody13
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study13
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis13
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis12
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)12
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis11
Utilization and tolerance of beta-blockers among patients with AL amyloidosis10
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures10
Brain MRI in patients with V30M hereditary transthyretin amyloidosis10
Refining prognostication in systemic AL amyloidosis: limited value of dFLC10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?9
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis9
Correction9
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee9
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation9
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis9
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?9
Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis8
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study8
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant8
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study8
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution8
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)8
Incidence and predictors of sudden death in patients with cardiac amyloidosis8
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines8
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy7
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis7
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours7
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis7
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy7
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies7
0.090123176574707